Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS Currently down 0.64 (-2.60%) in today's trading session

Track congressional stock trades in Arcutis Biotherapeutics, Inc. (ARQT). Analyze trading activity from Nancy Pelosi and other members of Congress with real-time financial disclosure data, interactive price charts, and detailed transaction records.

Arcutis Biotherapeutics, Inc. is currently trading at $23.95, positioned at 61% of its 52-week range ($11.86 – $31.77). View which politicians have recently bought or sold ARQT and how their trades align with market movements.

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio in real-time with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$23.95
24h Change
-0.64 (-2.60%)
52 Week Range
$11.86$31.77
View on NASDAQ

Arcutis Biotherapeutics, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ARQT

Select to highlight on chart
2 transactions
Compliance: 100%
Josh Gottheimer17 Apr 202319 May 2023PurchaseStock$1,001 - $15,000N/A (Price Data Unavailable)
Josh Gottheimer15 Jun 202222 Jul 2022PurchaseStock$1,001 - $15,000N/A (Price Data Unavailable)

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$2.97B

Volume

605.3K

Beta

1.74

P/E Ratio

-184.23

Fundamentals

EPS

$-0.13

Div. Yield

Open

$24.44

Day Range

$23.53 — $24.44

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Todd Franklin Watanabe
IPO Date
2020-01-31

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical tri...

Earnings

Next Report

Q1 2026

5 May

EPS Est.

$-0.03

Rev. Est.

$104.8M

Days Until

54

Recent Quarters

Q4 202525 Feb
EPS$0.13
Beat 40.8%
Q3 202528 Oct
EPS$0.06
Beat 160.0%
Q2 20256 Aug
EPS$-0.13
Beat 27.8%
Q1 20256 May
EPS$-0.20
Beat 4.8%
Q4 202425 Feb
EPS$-0.09
Beat 67.9%
Q3 20246 Nov
EPS$-0.33
Beat 21.4%
Q2 202414 Aug
EPS$-0.42
Beat 12.5%
Q1 202414 May
EPS$-0.32
Beat 46.7%
Q4 202327 Feb
EPS$-0.72
Miss 10.8%
Q3 20233 Nov
EPS$-0.73
Beat 18.9%
Q2 20238 Aug
EPS$-1.16
Beat 4.9%
Q1 20239 May
EPS$-1.31
Miss 0.8%
Q4 202228 Feb
EPS$-1.18
Beat 13.9%
Q3 20228 Nov
EPS$-1.89
Miss 22.7%
Q2 20224 Aug
EPS$-1.31
Beat 5.1%
Q1 20225 May
EPS$-1.27
Beat 10.6%
Q4 202122 Feb
EPS$-1.42
Miss 0.7%
Q3 20214 Nov
EPS$-1.14
Miss 4.6%
Q2 20215 Aug
EPS$-0.84
Beat 7.7%
Q1 20214 May
EPS$-0.76
Beat 20.8%
Q4 202016 Feb
EPS$-0.79
Beat 11.2%
Q3 20205 Nov
EPS$-1.01
Miss 6.3%
Q2 202011 Aug
EPS$-0.94
Miss 11.9%
Q1 202012 May
EPS$-1.15
Miss 25.0%
Q4 201919 Mar
EPS$-6.18
Beat 32.9%
Q4 201931 Jan
EPS$-0.40
Q1 201930 Jun
EPS$-0.22
Q4 201831 Mar
EPS$-0.17
Q3 201831 Dec
EPS$-0.15
Q2 201830 Sept
EPS$-0.21
Q1 201830 Jun
EPS$-0.08
Q4 201731 Mar
EPS$-0.08

1 politician traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

LLY

Eli Lilly and Company

47
$999.84-1.51 (-0.15%)
Healthcare
Held by same politician
Same sector: Healthcare
1 politician
View Stock

NVDA

NVIDIA Corporation

20
$186.03+1.26 (+0.68%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

PTSNX

PIMCO Short Term I-3

17
$9.680.00 (0.00%)
Held by same politician
1 politician
View Stock
Pelosi TrackerJoin our Discord © 2026 - All rights reserved. This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.